AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 20424554
Drug: IL-6 -572C/G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL-6 -572C/G polymorphism
Trial: 20424554
Drug: IL-10 -1082A/G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL-10 -1082A/G polymorphism
Trial: 20426845
Drug: Insulin like
RxNorm normalized name: IGF 1 - Insulin like growth factor 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin like growth factor-I (IGF-I) in patients with aSAH, mean IGF-I concentrations for days one to five were 8.1 +/- 3.5 nmol/l.
Trial: 20426845
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (elective aneurysm surgery), mean IGF-I concentrations for days one to five were 11.2 +/- 3.1 nmol/l.
Trial: 20427509
Drug: l-T(4) replacement
RxNorm normalized name: L-3972-T
DrugBank: L-3972-T (DB17441)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l-T(4) replacement therapy
Trial: 20427701
Drug: Oral forodesine
RxNorm normalized name: Forodesine
DrugBank: Forodesine (DB06185)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Oral forodesine (200 mg/d) for up to 24 weeks
Trial: 20429726
Drug: Lipiodol injection
RxNorm normalized name: doxorubicin hydrochloride liposome Injection [LipoDox]
DrugBank: Ethiodized oil (DB00965)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipiodol injection during flexible cystoscopy into the submucosa of the bladder wall
Trial: 20429726
Drug: Lipiodol injection
RxNorm normalized name: doxorubicin hydrochloride liposome Injection [LipoDox]
DrugBank: Ethiodized oil (DB00965)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipiodol injection
Trial: 20429821
Drug: Fluticasone propionate/salmeterol
RxNorm normalized name: fluticasone propionate/salmeterol 100/50 MCG/INHAL Dry Powder Inhaler, 14 Blisters
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone propionate/salmeterol 100/50 microg combination (FSC)
Trial: 20429821
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (FSC and FP)
Trial: 20430469
Drug: Gefitinib 250
RxNorm normalized name: gefitinib 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gefitinib 250 mg daily
Trial: 20432813
Drug: One-year lifestyle
RxNorm normalized name: segesterone
DrugBank: Segesterone (DB14584)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One-year lifestyle intervention program (physical activity, nutrition course, behavioral therapy)
Trial: 20433539
Drug: Treatment for
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for hypertension (specifics not provided)
Trial: 20433746
Drug: New electronic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New electronic device for self-injection of subcutaneous interferon beta-1a, 44 mcg three times weekly, for 12 weeks.
Trial: 20433746
Drug: New electronic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New electronic device for self-injection of subcutaneous interferon beta-1a.
Trial: 20435233
Drug: Caspofungin (70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caspofungin (70 mg for one dose, followed by 50 mg daily)
Trial: 20435233
Drug: Micafungin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micafungin (100 mg daily)
Trial: 20435244
Drug: Leuprolide acetate
RxNorm normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leuprolide acetate 3.75-mg depot, administered as 6 monthly intramuscular injections.
Trial: 20435244
Drug: Leuprolide acetate
RxNorm normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leuprolide acetate 3.75-mg depot
Trial: 20439622
Drug: Eliglustat tartrate
RxNorm normalized name: eliglustat tartrate
DrugBank: Eliglustat (DB09039)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Eliglustat tartrate (Genz-112638) administered twice daily at 50- or 100-mg doses based on plasma drug concentrations.
Trial: 20442365
Drug: Cytarabine-based induction
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cytarabine-based induction therapy followed by 1 consolidation
Trial: 20444959
Drug: Breakfast (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Breakfast (500 kcal, 21 g protein)
Trial: 20446946
Drug: Aspirin (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (single antiplatelet therapy)
Trial: 20447528
Drug: MR-proANP (≥120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MR-proANP (≥120 pmol/l)
Trial: 20453640
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (Abciximab administered in 1086 patients)
Trial: 20456292
Drug: Injecting drugs
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injecting drugs
Trial: 20456292
Drug: Using illegal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Using illegal drugs before or during sex
Trial: 20458050
Drug: Cediranib (45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cediranib (45 mg/d)
Trial: 20460644
Drug: Flavopiridol (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flavopiridol (40 mg/m2 IV bolus + 60 mg/m2 continuous IV infusion)
Trial: 20461780
Drug: Rituximab 1000
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab 1000 mg intravenously at baseline and week 2
Trial: 20462451
Drug: Fertility treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fertility treatments
Trial: 20463041
Drug: Habitual dietary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Habitual dietary ALA intake (1-g increment)
Trial: 20463041
Drug: Twin with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twin with 1-g higher ALA intake compared to co-twin
Trial: 20465593
Drug: Wireless motility
RxNorm normalized name: careless weed pollen extract
DrugBank: Amaranthus palmeri pollen (DB10459)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wireless motility capsule (WMC) and Radiopaque markers (ROM)
Trial: 20466783
Drug: Insulin suppression
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin suppression of lipolysis
Trial: 20466853
Drug: Dasatinib 50
RxNorm normalized name: dasatinib 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dasatinib 50 mg by mouth twice per day (or 100 mg daily) for the first 14 days of each of 8 cycles of hyper-CVAD, followed by maintenance daily dasatinib and monthly vincristine and prednisone for 2 years.
Trial: 20466853
Drug: Dasatinib with
RxNorm normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Dasatinib with chemotherapy
Trial: 20471725
Drug: Butyrate enemas
RxNorm normalized name: butyrate
DrugBank: Butyric Acid (DB03568)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Butyrate enemas (100mM sodium butyrate, 60 ml daily for 20 days)
Trial: 20472746
Drug: Intravitreal pegaptanib
RxNorm normalized name: pegaptanib
DrugBank: Pegaptanib (DB04895)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravitreal pegaptanib 0.3 mg administered every 6 weeks for 48 weeks
Trial: 20478057
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose cyclophosphamide (300 mg/m2) followed by GM-CSF + GV1001 vaccinations
Trial: 20484311
Drug: Asymmetric dimethylarginine
RxNorm normalized name: dimethylamine
DrugBank: N,N-dimethylarginine (DB01686)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Asymmetric dimethylarginine (ADMA) levels in the highest quartile (> 0.84 mumol/l)
Trial: 20484443
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E (200 IU daily for 1 year)
Trial: 20484456
Drug: Low intake
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low intake of n-3 LCPUFAs (< approximately 0.30 g/d)
Trial: 20489620
Drug: Imatinib (dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imatinib (dose escalation)
Trial: 20489620
Drug: Modification of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modification of imatinib dose to achieve a target imatinib plasma level
Trial: 21140148
Drug: Standard imatinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard imatinib dosing
Trial: 20491740
Drug: 1200 IU
RxNorm normalized name: Vitamin E 1200 IU Oral Capsule, Liquid Filled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1200 IU vitamin D3 once daily for 12 months
Trial: 20491780
Drug: Inotuzumab ozogamicin
RxNorm normalized name: Inotuzumab ozogamicin
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Inotuzumab ozogamicin (1.3 mg/m²)
Trial: 20491780
Drug: Inotuzumab ozogamicin
RxNorm normalized name: Inotuzumab ozogamicin
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Inotuzumab ozogamicin (1.8 mg/m²)
Trial: 20491780
Drug: Inotuzumab ozogamicin
RxNorm normalized name: Inotuzumab ozogamicin
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Inotuzumab ozogamicin (both doses)
Trial: 20508619
Drug: Cyclophosphamide 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide 400 mg/m(2)
Trial: 20508619
Drug: Cyclophosphamide 500
RxNorm normalized name: cyclophosphamide 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide 500 mg/m(2)
Trial: 20511445
Drug: Lp(a) <10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lp(a) <10 mg/L and Hb A(1c) <5%
Trial: 20511662
Drug: Intermediate risk
RxNorm normalized name: Prevotella intermedia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermediate risk group (with at least one of: unmutated IGHV genes and/or IGHV3-21 usage, 11q deletion, β-2 microglobulin greater than 4 mg/L)
Trial: 20516271
Drug: 10 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/kg once-daily lamivudine (3TC) for children below 17 kg
Trial: 20516271
Drug: 8 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg/kg once-daily lamivudine (3TC) for children over 17 kg
Trial: 20516271
Drug: Didanosine-lamivudine-efavirenz treatment
RxNorm normalized name: efavirenz / lamivudine / tenofovir disoproxil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Didanosine-lamivudine-efavirenz treatment
Trial: 20518811
Drug: Pramlintide added
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pramlintide added to mealtime insulin
Trial: 20519658
Drug: Antibody positive
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibody positive subjects (GAD-65 and IA-2 autoantibodies)
Trial: 20519658
Drug: Antibody negative
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibody negative subjects
Trial: 20522711
Drug: Fibril-reactive, amyloidolytic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibril-reactive, amyloidolytic murine IgG1 mAb 11-1F4 labeled with I-124, infused with less than 1 mg (∼ 74 MBq) of GMP-grade antibody.
Trial: 20523092
Drug: Oxaliplatin 70
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxaliplatin 70 mg/m(2) on days 1 and 15, irinotecan 100 mg/m(2) on days 8 and 22, capecitabine (dose levels 1-5, between 800 and 1,600 mg/m(2)) on days 1-29 every 5 weeks.
Trial: 20523092
Drug: Capecitabine at
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine at the recommended dose of 1,400 mg/m(2) daily.
Trial: 20525721
Drug: Trimodality therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimodality therapy (induction chemotherapy with cisplatin 75 mg·m⁻² and pemetrexed 500 mg·m⁻², followed by extrapleural pneumonectomy and post-operative radiotherapy at 54 Gy, 30 fractions)
Trial: 20529243
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy (simvastatin and ezetimibe)
Trial: 20530034
Drug: Riociguat 1.0-2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Riociguat 1.0-2.5 mg t.i.d. titrated according to systemic systolic blood pressure (SBP)
Trial: 20530048
Drug: Doxorubicin (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin (60 mg·m⁻²) plus valproic acid
Trial: 20530284
Drug: Radioimmunotherapy (RIT)
RxNorm normalized name: mumps virus vaccine live, RIT-4385 strain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radioimmunotherapy (RIT) using yttrium-90-ibritumomab-tiuxetan (15 MBq [0.4 mCi]/kg) with reduced-intensity conditioning (RIC) using fludarabine (90 mg/m(2)) and 2 Gy total body irradiation followed by allogeneic hematopoietic cell transplantation (HCT)
Trial: 20538956
Drug: mRNA content
RxNorm normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 Injectable Suspension [Spikevax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mRNA content of peroxisome proliferator-activated receptor γ coactivator 1-α in critically ill patients.
Trial: 20545713
Drug: Fluid administration
RxNorm normalized name: Fluid Administration Set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluid administration (200 mL of hydroxyethyl starch, HES 130/0.4)
Trial: 20545869
Drug: Increase in
RxNorm normalized name: Incruse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increase in device size (1-cc)
Trial: 20549827
Drug: Aromatase inhibitors
RxNorm normalized name: Aromatase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aromatase inhibitors (letrozole or exemestane)
Trial: 20551376
Drug: BACOPP regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BACOPP regimen (bleomycin, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) administered in 6 to 8 cycles; 75% of treatment courses were administered according to protocol
Trial: 20551454
Drug: Esomeprazole (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole (40 mg for 2 weeks)
Trial: 20555351
Drug: Narrow-band UVB
RxNorm normalized name: Band-Aid Hurt-Free
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Narrow-band UVB radiation therapy (NB-UVB) for 6 weeks
Trial: 20555351
Drug: Narrow-band UVB
RxNorm normalized name: Band-Aid Hurt-Free
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Narrow-band UVB radiation therapy (NB-UVB)
Trial: 20559034
Drug: Single vaccination
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single vaccination with a split virion, inactivated, adjuvanted pandemic H1N1 influenza vaccine (A/California/7/2009)
Trial: 20560883
Drug: Rectal luminal
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rectal luminal lactate concentration
Trial: 20560883
Drug: Rectal-arterial difference
RxNorm normalized name: Echinacea, aerial parts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal-arterial difference of lactate concentration
Trial: 20560883
Drug: Blood pressure,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood pressure, noradrenaline dose, central venous oxygen saturation
Trial: 20562526
Drug: Chloroquine or
RxNorm normalized name: chloroquine Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloroquine or other autophagy/lysosome inhibitors
Trial: 20564111
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of tumor diameter >5 cm and N+
Trial: 20564750
Drug: Multilevel surgical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multilevel surgical treatment (uvulopalatopharyngoplasty, tonsillectomy, genioglossus advancement, with or without hyoid suspension)
Trial: 20564750
Drug: Multilevel surgical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multilevel surgical treatment
Trial: 20573151
Drug: Acupuncture (twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture (twice on the same day at acupuncture point GV20 and bilaterally at points BL67, LI4 and SP6)
Trial: 20576011
Drug: IVIG administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IVIG administration
Trial: 20579630
Drug: 20% topical
RxNorm normalized name: Urea 20% Topical cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20% topical autologous serum
Trial: 20579630
Drug: No use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No use of topical autologous serum
Trial: 20581689
Drug: Fibrinogen levels
RxNorm normalized name: fibrinogen
DrugBank: Fibrinogen human (DB09222)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibrinogen levels in the highest tertile (>406 mg/dL)
Trial: 20581689
Drug: Fibrinogen (as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibrinogen (as a linear variable) per 100 mg/dL increase
Trial: 20582937
Drug: Bortezomib 1.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bortezomib 1.3 mg/m(2) with VXLD chemotherapy
Trial: 20582937
Drug: Bortezomib 1
RxNorm normalized name: bortezomib 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bortezomib 1 mg/m(2) with VXLD chemotherapy
Trial: 20582937
Drug: Bortezomib with
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bortezomib with VXLD chemotherapy
Trial: 20584275
Drug: Behavior therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavior therapy (N = 12)
Trial: 20584542
Drug: Pazopanib 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pazopanib 800 mg once daily until PD or unacceptable toxicity
Trial: 20591191
Drug: Probiotics (Lactobacillus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotics (Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14), 2 capsules a day for 6-12 weeks, up to the 24th-25th week of gestation.
Trial: 20594195
Drug: Bendamustine 90
RxNorm normalized name: bendamustine 90 mg/mL intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bendamustine 90 mg/m²
Trial: 20594195
Drug: Bendamustine 120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bendamustine 120 mg/m²
Trial: 20595284
Drug: Adalimumab 40
RxNorm normalized name: ADALIMUMAB 40MG/0.8ML INJ,PEN,KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab 40 mg subcutaneous injections every other week
Trial: 20599188
Drug: GSK598809 (selective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK598809 (selective D(3) receptor antagonist)
Trial: 20605934
Drug: SU14813 (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SU14813 (200 mg/day on schedule 4/1)
Trial: 20605934
Drug: SU14813 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SU14813 (100 mg/day with continuous daily dosing)
Trial: 20606544
Drug: Rituximab administered
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab administered intravenously at 375 mg/m2 on each of 4 consecutive weeks with conventional immunotherapy (Group I and II)
Trial: 20606544
Drug: Rituximab administered
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab administered intravenously at 375 mg/m2 on each of 4 consecutive weeks without conventional immunotherapy (Group III)
Trial: 20606544
Drug: Rituximab dosing
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab dosing based on body weight
Trial: 20606683
Drug: Aromatase inhibitor
RxNorm normalized name: Aromatase inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aromatase inhibitor therapy (AI); specific dosage and duration not mentioned.
Trial: 20606683
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (without AIMSS); specific dosage and duration not mentioned.
Trial: 20608766
Drug: Baseline IP-10
RxNorm normalized name: IP-2018
DrugBank: IP-2018 (DB19049)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline IP-10 < 150 pg/ml
Trial: 20609468
Drug: Olaparib 100
RxNorm normalized name: olaparib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olaparib 100 mg twice daily
Trial: 20609706
Drug: Sirna-027 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sirna-027 (100 and 200 microg doses)
Trial: 20610186
Drug: Donepezil 10
RxNorm normalized name: donepezil 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donepezil 10 mg daily for 90 days
Trial: 20617532
Drug: Presence of
RxNorm normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Presence of anti-Sa antibodies at inclusion, especially at higher titers
Trial: 20617532
Drug: Low titer
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low titer of any particular antibody
Trial: 20617532
Drug: Reversion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reversion of RF and anti–CCP-2 antibodies
Trial: 20617532
Drug: Initial positivity
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial positivity for RF and anti–CCP-2 antibodies
Trial: 20617532
Drug: Presence of
RxNorm normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Presence of anti-Sa antibodies